Christopher Marai
Stock Analyst at Nomura
(2.43)
# 2,412
Out of 4,761 analysts
33
Total ratings
51.61%
Success rate
10.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $8.18 | +11,635.94% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $38.75 | -14.84% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $5.78 | +1,457.09% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $250.59 | -70.47% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $4.22 | +279.15% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $140.64 | +178.73% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.79 | +1,799.44% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $106.28 | +116.41% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $16.38 | -26.74% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $15.56 | +22.11% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.53 | +2,710.46% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $8.18
Upside: +11,635.94%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $38.75
Upside: -14.84%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $5.78
Upside: +1,457.09%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $250.59
Upside: -70.47%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $4.22
Upside: +279.15%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $140.64
Upside: +178.73%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.79
Upside: +1,799.44%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $106.28
Upside: +116.41%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $16.38
Upside: -26.74%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $15.56
Upside: +22.11%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.53
Upside: +2,710.46%